Sanofi CEO Olivier Brandicourt and GlaxoSmithKline CEO Andrew Witty said that a changing of the guard in the federal government will not bring about an easing of price pressures on drugmakers, but it might allow more mergers and acquisitions. Pharmacy benefit managers are adept at forcing drugmakers to compete by offering discounts and rebates.